Phase 1 study of lenzilumab, a recombinant anti–human GM-CSF antibody, for chronic myelomonocytic leukemia
Journal article published in 2020 by
Mrinal M. Patnaik,
David A. Sallman,
Abhishek A. Mangaonkar,
Rachel Heuer,
Jeffery Hirvela,
Darci Zblewski,
Aref Al-Kali,
Moritz Binder 
,
Maria E. Balasis ,
Hannah Newman,
Christopher Letson,
Traci L. Kruer ,
Naseema Gangat,
Rami S. Komrokji,
Ayalew Tefferi
and other authors.
,
Maria E. Balasis ,
Hannah Newman,
Christopher Letson,
Traci L. Kruer ,
Naseema Gangat,
Rami S. Komrokji,
Ayalew Tefferi
and other authors.
Distributing this paper is prohibited by the publisher
Full text: Unavailable
Preprint: archiving forbidden
Published version:
archiving forbidden
Data provided by 
Abstract
In this phase 1 trial, inhibition of granulocyte-macrophage colony-stimulating factor (GM-CSF) was associated with clinically meaningful responses in 5 of 15 patients with relapsed or refractory chronic myelomonocytic leukemia (CMML). Preliminary data suggest that this approach may be tractable in CMML bearing activating NRAS mutations.